Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population
Our real-world data support previously reported findings and further validate ICI based therapy as the standard of care for patients with advanced BTCs.
Authors
- Alicia C Marín (ORCID: https://orcid.org/0000-0003-1008-1812)
- Janett Fischer (ORCID: https://orcid.org/0000-0002-8710-101X)
- Sebastian Ebel (ORCID: https://orcid.org/0000-0001-6856-6455)
- Sonja Gehring
- Aaron Schindler (ORCID: https://orcid.org/0009-0001-5245-6048)
- Florian van Bömmel (ORCID: https://orcid.org/0000-0003-2679-0672)
- Jack Chater
- Udo Lindig
- Raphael Mohr (ORCID: https://orcid.org/0000-0003-2403-4275)
- Christa Elisabeth Müller (ORCID: https://orcid.org/0000-0002-0013-6624)
- Florian Gerhardt
- Maik Schwarz
- Mara Egerer
Institutions
- Philipps University of Marburg (DE)
- Vodafone (Germany) (DE)
- University Hospital Leipzig (DE)
- Jena University Hospital (DE)
- University Hospital Magdeburg (DE)
- Klinikum Chemnitz (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Leipzig University (DE)
- Otto-von-Guericke-Universität Magdeburg (DE)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1007/s00432-025-06239-1
- Citations
- 2
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Universität Leipzig